What's new

Orphan designation: Humanised monoclonal antibody targeting B-cell maturation antigen conjugated with maleimidocaproyl monomethyl auristatin F Treatment of multiple myeloma, 16/10/2017 Withdrawn

Orphan designation: Humanised monoclonal antibody targeting B-cell maturation antigen conjugated with maleimidocaproyl monomethyl auristatin F Treatment of multiple myeloma, 16/10/2017 Withdrawn

Feb 19, 2025 - 09:55
 0
Orphan designation: Humanised monoclonal antibody targeting B-cell maturation antigen conjugated with maleimidocaproyl monomethyl auristatin F Treatment of multiple myeloma, 16/10/2017 Withdrawn
Orphan designation: Humanised monoclonal antibody targeting B-cell maturation antigen conjugated with maleimidocaproyl monomethyl auristatin F Treatment of multiple myeloma, 16/10/2017 Withdrawn
Read More

Tags:

Previous Article

INVEST SAUDI RETURNS TO MIPIM WITH A WEALTH OF NEW INVESTMENT OPPORTUNITIES

Next Article

Human medicines European public assessment report (EPAR): Blenrep, belantamab ma...

Related Posts

ICH Guideline M13A on bioequivalence for immediate-release solid oral dosage forms - Scientific guideline

ICH Guideline M13A on bioequivalence for immediate-rele...

Feb 26, 2025  0

Human medicines European public assessment report (EPAR): Vueway, Gadopiclenol, Date of authorisation: 07/12/2023, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 9, 2025  0

Human medicines European public assessment report (EPAR): Copalia HCT, amlodipine,valsartan,hydrochlorothiazide, Date of authorisation: 03/11/2009, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 12, 2025  0